42PLUS1 – DxPx Conference Builds Europe’s Largest Prized Business Plan Competition With Over 1,000,000 USD Funding – Application Phase Runs

Great opportunity for young entrepreneurs – 1,000,000 USD is there to win for the most innovative business ideas. The winners will be elected from a renowned jury of industry experts and investors at the 42PLUS1 business plan competition at the DxPx Conference in November. Start-ups can apply online via www.42plus1.com

DUSSELDORF, Germany – The DxPx Conference – is an established Industry & Investor Partnering Conference for executives of the Diagnostics, Precision Medicine and Life Science Tools industry. With many innovations and tests from these industries having been critical in battling the Corona pandemic, the organizers of the DxPx Conference have decided to support young companies even more. Dr. Mirko Stange, founder of the DxPx Conference and the initiator of the 42PLUS1 business plan competition states “This pitch award is the first one focusing entirely on an industry that we believe will gain more and more importance in our every day’s life. We are excited that five months prior to the competition, we can already announce an award of over 1,000,000 USD for three innovative startups with break-through technologies.”

Founders offering novel solutions in Diagnostics, Precision Medicine and Life Science Tools are encouraged to submit their business plans online. All received applications will be rated by a renowned jury of venture capital firms and industry experts and the top eight startups will be invited to pitch live on stage at the DxPx Conference in Dusseldorf, Germany on November 16th, 2021. A first chance to win a Wildcard to present among the top eight will be granted to the winner of the US version of 42PLUS1 that will take place at the upcoming, all digital DxPx US Conference on July 27th, at Chicago time. The DxPx US will connect leaders of the industries as well as renowned investors and startup founders with an American focus. With strong partners like Brown Gibbons Lang & Company, McDermott Will & Emery, or Roche Diagnostics, the DxPx Conference offers the perfect environment for startups and growth companies to position themselves in front of a relevant audience of industry partners and investors.

With the application process already in full motion, 42PLUS1 is receiving a notable number of pitch submissions. Applications for the DxPx US award are still open until June 25th and can be submitted on the 42PLUS1 website (www.42plus1.com).

About 42PLUS1®:

With the already committed 1,000,000 USD, 42PLUS1 is the highest-prized, industry dedicated business plan competition in Europe and one of the biggest worldwide dedicated to the DxPx Galaxy of Diagnostics, Precision Medicine and Life Science Tools. It underlines SLS Partnering’s commitment to support startups and growth companies and can now make an even bigger difference for the whole startup universe.

About DxPx®:

DxPx was first hosted in 2019 as an international Investor & Industry Partnering Conference for executives from the Diagnostics, Precision Medicine & Life Science Tools industries to explore financing, licensing and M&A opportunities. The annual flagship conference takes place each November in Dusseldorf, Germany and is accompanied with satellite conferences in the US and China throughout the year.

About SLS Partnering:

SLS Partnering is an event & marketing agency that tailors its services to the specific needs of the Life Science industry. Built by scientists and marketeers, SLS Partnering is your trusted partner to translate technology and scientific content into high-quality marketable stories that trigger interest and emotion with customers and investors.

Press Contact

Jacqueline Soldan 
SLS Partnering GmbH 

Social Sharing

Did you like the article? If so, we would be happy if you share it with your friends and acquaintances!

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.